A share price of CytomX Therapeutics Inc [CTMX] is currently trading at $2.37, down -0.84%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value.
From an analyst’s perspective:
CytomX Therapeutics Inc [NASDAQ: CTMX] stock has seen the most recent analyst activity on July 31, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $7. Previously, H.C. Wainwright upgraded its rating to Buy on May 15, 2025, and kept the price target unchanged to $5. Piper Sandler upgraded its rating to a Overweight and increased its price target to $3.50 on May 28, 2024. Wedbush upgraded its rating to a Outperform but $8 remained the price target by the analyst firm on May 09, 2024. Jefferies upgraded its rating to Buy for this stock on May 06, 2024, and upped its price target to $8. In a note dated April 22, 2024, JP Morgan upgraded an Neutral rating on this stock.
CytomX Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $0.40 and $3.10. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. CytomX Therapeutics Inc [NASDAQ: CTMX] shares were valued at $2.37 at the most recent close of the market. An investor can expect a potential return of 195.36% based on the average CTMX price forecast.
Analyzing the CTMX fundamentals
Trailing Twelve Months sales for CytomX Therapeutics Inc [NASDAQ:CTMX] were 147.56M which represents 22.80% growth. Gross Profit Margin for this corporation currently stands at 0.65% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.28%. To continue investigating profitability, this company’s Return on Assets is posted at 0.42, Equity is -5.53 and Total Capital is 0.74. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for CytomX Therapeutics Inc [NASDAQ:CTMX] is 1.73. As well, the Quick Ratio is 1.73, while the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 2.53, the price to book ratio is 7.63 and price to earnings (TTM) ratio is 4.78.
Transactions by insiders
Recent insider trading involved Ogden Christopher, Chief Financial Officer, that happened on Jun 16 ’25 when 10614.0 shares were sold. Chief Financial Officer, Ogden Christopher completed a deal on Jun 13 ’25 to sell 1641.0 shares. Meanwhile, SVP, Chief Scientific Officer BELVIN MARCIA sold 13884.0 shares on Jun 16 ’25.
